PPARG and Chagas disease: Taking all this into account, our group has led research on the effect of different PPAR agonists in the context of Chagas disease (38, 60–63), that bear in common anti-inflammatory properties besides their effect on carbohydrate (PPARγ) or lipid (PPARα) metabolism.